Macrophage foam cells are the major culprits in atherosclerotic lesions, having a prominent role in both lesion initiation and progression. With atherosclerosis being the main factor underlying cardiovascular complications, there is a long-standing interest on finding ways to reverse lipid buildup in plaques. Studies have shown that promoting reverse cholesterol transport (RCT) from macrophage foam cells is anti-atherogenic because it alleviates the cholesterol burden of the plaques. The goal of this thesis was to gain insight into the mechanisms that govern cholesterol efflux from macrophage foam cells. The first part of this study looked at the ability of different oxysterols to promote cholesterol efflux in unloaded as compared to lipid-loaded macrophages, and our major finding here is that epoxycholesterol decreases efflux in lipid-loaded macrophages. It appears that epoxycholesterol does so by impairing the release cholesterol from its cellular storage site, the lipid droplet (LD), where it accumulates in the form of cholesteryl esters (CE). These results highlighted the importance of cholesterol release from LDs for efflux; indeed, this process is increasingly being recognized as the rate-limiting step for RCT in vivo. Subsequent experiments aimed at elucidating the mechanisms that govern LD CE hydrolysis in macrophage foam cells lead to the discovery of a novel pathway involved in cholesterol efflux. Macrophage CE hydrolysis is classically defined as being entirely dependent on neutral CE hydrolases. In the second part of this study, we demonstrate that in addition to the canonical CE hydrolases, which mediate neutral lipid hydrolysis, lysosomal acid lipase (LAL) also participates in the hydrolysis of cytoplasmic CE. Autophagy is specifically triggered in macrophages by atherogenic lipoproteins and delivers LD CE to LAL in lysosomes, thus generating free cholesterol for efflux. This autophagy-mediated cholesterol efflux is a process that is primarily dependant on the ABCA1 transporter and, importantly, is important for whole-body RCT. Overall, the studies presented in this thesis support that macrophage LD CE hydrolysis is rate-limiting for cholesterol efflux and shed light on the mechanisms of cholesterol mobilization for efflux in macrophage foam cells.

Macrophage foam cells are the major culprits in atherosclerotic lesions, having a prominent role in both lesion initiation and progression. With atherosclerosis being the main factor underlying cardiovascular complications, there is a long-standing interest on finding ways to reverse lipid buildup in plaques. Studies have shown that promoting reverse cholesterol transport (RCT) from macrophage foam cells is anti-atherogenic because it alleviates the cholesterol burden of the plaques. The goal of this thesis was to gain insight into the mechanisms that govern cholesterol efflux from macrophage foam cells. The first part of this study looked at the ability of different oxysterols to promote cholesterol efflux in unloaded as compared to lipid-loaded macrophages, and our major finding here is that epoxycholesterol decreases efflux in lipid-loaded macrophages. It appears that epoxycholesterol does so by impairing the release cholesterol from its cellular storage site, the lipid droplet (LD), where it accumulates in the form of cholesteryl esters (CE). These results highlighted the importance of cholesterol release from LDs for efflux; indeed, this process is increasingly being recognized as the rate-limiting step for RCT in vivo. Subsequent experiments aimed at elucidating the mechanisms that govern LD CE hydrolysis in macrophage foam cells lead to the discovery of a novel pathway involved in cholesterol efflux. Macrophage CE hydrolysis is classically defined as being entirely dependent on neutral CE hydrolases. In the second part of this study, we demonstrate that in addition to the canonical CE hydrolases, which mediate neutral lipid hydrolysis, lysosomal acid lipase (LAL) also participates in the hydrolysis of cytoplasmic CE. Autophagy is specifically triggered in macrophages by atherogenic lipoproteins and delivers LD CE to LAL in lysosomes, thus generating free cholesterol for efflux. This autophagy-mediated cholesterol efflux is a process that is primarily dependant on the ABCA1 transporter and, importantly, is important for whole-body RCT. Overall, the studies presented in this thesis support that macrophage LD CE hydrolysis is rate-limiting for cholesterol efflux and shed light on the mechanisms of cholesterol mobilization for efflux in macrophage foam cells.

京都大学 / 0048 / 新制・課程博士 / 博士(医学) / 甲第18145号 / 医博第3865号 / 新制||医||1002(附属図書館) / 31003 / 京都大学大学院医学研究科医学専攻 / (主査)教授 萩原 正敏, 教授 柳田 素子, 教授 稲垣 暢也 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM

In this study, we examined the effects of thyroid hormone on regulatory processes of cholesterol metabolism. Specifically, the pathways of cholesterol synthesis and cholesterol efflux were investigated. Hepatic HMG-CoA reductase (HMGR) is the rate-limiting enzyme in cholesterol synthesis. Hypothyroid rats exhibit decreased expression of this gene, which can be induced by subsequent treatment with thyroid hormone. The mechanism of this activation was previously unknown. Utilizing in vivo electroporation, we identified HMGR promoter elements necessary for the induction of HMGR by thyroid hormone. The -316/-321 element, the sterol response element, and nuclear factor-y site were all found to be necessary to induce HMGR promoter activity by thyroid hormone. We used electrophoretic mobility shift assays (EMSA) and chromatin immunoprecipitation (ChIP) studies to demonstrate increased binding of upstream transcription factor-2 (USF-2) to the -316/-321 element in the HMGR promoter in response to thyroid hormone. Finally, co-electroporation of the wild-type HMGR plasmid with siRNA to USF-2, SREBP-2, or NF-Y nearly abolished the T3 induction as measured by promoter activity. Microarray and real-time PCR analysis demonstrated an induction of the apolipoproteins ApoA-I and ApoA-IV mRNA by T3. Serum levels of ApoA-I and ApoA-IV proteins were induced by T3. We collected serum from rats treated with or without T3 and used these sera in an in vitro macrophage efflux model. We found that T3 promoted cholesterol efflux via the ABCA1 cholesterol transporter and not via the ABCG1 transporter. We propose that the induction of serum ApoA-I and ApoA-IV by thyroid hormone promotes cholesterol efflux via the ABCA1 cholesterol transporter. Hepatic ABCG5 and ABCG8 are cholesterol transporters that promote biliary secretion of cholesterol. We utilized EMSAs to scan the shared ABCG5/G8 rat promoter for a thyroid hormone response element (TRE). We identified a TRß binding site at -392/-376 of the ABCG8 promoter. Collectively, these observations provide new insight into the cholesterol-lowering function of thyroid hormone.

Charles University, Faculty of Pharmacy in Hradec Králové, Department of Biological and Medical Sciences University of Vienna, Faculty of Life Sciences, Department of Pharmacognosy Candidate: Lenka Kovářová Supervisor: Pharmdr. Miroslav Kovařík, Ph.D. Consultant: Dr. Angela Ladurner Title of the diploma thesis: Characterization of a synthetic leoligin derivative, with agonistic FXR and enhancing macrophage cholesterol efflux activity Atherosclerosis is a pathologic multifactorial process triggering the development of cardiovascular diseases, which are the leading causes of death in the western world. The initial phase of atherosclerosis is characterized by the accumulation of lipid particles, mainly low-density lipoproteins (LDL) and macrophage-derived foam cells in large arteries, leading to the gradual thickening of the vessel wall. These progressive alterations elicit plaque formation, followed by rupture, thrombosis and finally can lead to a cardiovascular event. Reverse cholesterol transport is an important preventive mechanism, which ensures removal of excessive atherogenic lipoproteins from macrophages. This efflux is facilitated by ATP binding cassette transporters, mainly ABCA1 and ABCG1 and in part by scavenger receptor B1 (SR-B1). Several nuclear receptors, including PPARγ, LXRα and LXRβ...

Os óxidos de colesterol modulam o desenvolvimento da aterosclerose por mediarem a síntese, captação e exportação de colesterol, além de inflamação e citotoxicidade na parede arterial. O exercício físico regular previne e regride a lesão aterosclerótica, por melhorar o perfil lipídico, transporte reverso de colesterol e defesas antioxidantes. A proteína cinase ativada por AMP (AMPK) é um importante mediador dos efeitos metabólicos do exercício físico. Em macrófagos, sua ativação vincula-se ao aumento no efluxo de colesterol e diminuição na captação de LDL. Entretanto, não está claro se o treinamento físico modula as concentrações de óxidos de colesterol, refletindo seu benefício sobre a prevenção da aterosclerose, e se esses efeitos podem ser mediados pela AMPK. O objetivo do presente estudo foi avaliar, em camundongos dislipidêmicos, o papel de 6 semanas de treinamento físico aeróbio sobre: o infiltrado de colesterol arterial e a distribuição de óxidos de colesterol no arco aórtico e no plasma; a expressão gênica de proteínas envolvidas na metabolização de óxidos de colesterol na parede arterial; e o efeito da ativação da AMPK em macrófagos, in vitro, sobre a concentração dos óxidos de colesterol e expressão de genes envolvidos na metabolização de óxidos de colesterol. Para tanto, camundongos machos knockout para apolipoproteína E, com 16 semanas de idade, alimentados com dieta padrão, foram incluídos no estudo. O treinamento físico foi realizado em esteira, 15 m/min, por 60 min, 5 dias/semana, durante 6 semanas. Lípides plasmáticos e glicose foram determinados por ensaio enzimático e glicosímetro, respectivamente, antes e após o treinamento físico. Colesterol arterial e óxidos de colesterol foram avaliados por cromatografia gasosa acoplada à espectrometria de massa. A expressão de genes envolvidos no metabolismo de lípides foi avaliada RT-qPCR. Os resultados foram comparados por ANOVA de um fator com pós-teste de Newman-Keuls ou teste t de Student. Peso corporal, colesterol total, TG, HDL-c, glicose e óxidos de colesterol no plasma foram semelhantes entre os grupos. O treinamento físico aumentou a concentração de 7alfa-OH C (70%) e reduziu a de colesterol (32%) na aorta. Além disso, o exercício físico aumentou a expressão gênica da Cyp27a1 (54%), Cd36 (75%), Cat (70%), Prkaa1 (AMPKalfa1) (40%) e Prkaa2 (AMPKalfa2) (51%) e reduziu Abcg1 (31%), Olr1 (LOX-1) (65%), Cyp7b1 (35%) e Ch25h (48%). Nenhuma alteração foi observada na expressão de Abca1, Nr1h3 (LXRalfa) e Nr1h2 (LXRbeta). Nos macrófagos, a ativação da AMPK por AICAR, reduziu o conteúdo de 7alfa-OH C após estimulo com HDL2. O tratamento com AICAR aumentou a expressão gênica de Abca1 (52%) e Cd36 (220%) e diminuiu Prkaa1 (19%) e Cyp27a1 (47%), e não alterou Abcg1, Nr1h3 e Nr1h2. Em conclusão, em camundongos dislipidêmicos, o treinamento físico aeróbio, por 6 semanas, aumentou a concentração de 7 beta -OH C, o que se vincula à maior expressão de Cd36 no arco aórtico. A rápida difusão de óxidos de colesterol, como via complementar ao transporte reverso de colesterol, pode também ser favorecida pelo aumento e redução, respectivamente, na expressão de Cyp27a1 e Cyp7b1, favorecendo maior liberação de 27-OH C das células. Juntamente com suas ações diretas que beneficiam o transporte reverso de colesterol, previamente descritas o treinamento físico diminui a concentração de colesterol na parede arterial, prevenindo a aterosclerose. Baseado nos ensaios in vitro a ativação da AMPK não parece contribuir para o aumento das concentrações de óxidos de colesterol após treinamento físico / Oxysterols modulate the development of atherosclerosis by mediating cholesterol synthesis, uptake and exportation as well as inflammation and cytotoxicity in the arterial wall. Regular physical exercise prevents and regresses atherosclerosis by improving lipid metabolism, reverse cholesterol transport and antioxidant defenses. AMP-activated protein kinase (AMPK) plays an important role in the beneficial metabolic adaptations of physical exercise. In macrophages, its activation is related to the enhancement in cholesterol efflux and reduction in LDL uptake. However, it is not clear whether exercise training benefits in atherosclerosis is mediated by its action in oxysterols concentrations, and whether this can be modulated by AMPK. The aim of this study was to evaluate the role of a 6-week aerobic exercise training program in dyslipidemic mice in the arterial and plasma accumulation of cholesterol and oxysterols subspecies; expression of genes related to oxysterols metabolisms in the aortic arch, and the effect of AMPK activation in macrophage on the concentration of oxysterols and expression of genes linked to oxysterols metabolism. Sixteen-week-old male apoE knockout mice fed a chow diet were included in the protocol. Animals were trained in a treadmill running, 15 m/min, 60 min, 5 days/week, during 6 weeks. Plasma lipids and glucose were determined by enzymatic techniques and glycosometer, respectively. Cholesterol in aortic arch and oxysterols were measured by gas chromatography/mass spectrometer. The expression of genes involved in lipid metabolism was determined by RT-qPCR. Results (mean ± SD) were compared by one-way ANOVA with Newman-Keuls posttest or Student\'s t-test. Body weight and plasma total cholesterol, TG, HDL-c, glucose, and oxysterols were similar among groups. The exercise training enhanced 7beta-hydroxycholesterol (70%) and reduced cholesterol (32%) in the aortic arch. In addition, exercise increased Cyp27a1 (54%), Cd36 (75%), cat (70%), Prkaa1 (AMPKalpha1) (40%) and Prkaa2 (AMPKalpha2) (51%) mRNA. No changes were observed in the expression of Abca1, Nr1h3 (LXRalpha) and Nr1h2 (LXRbeta). In macrophages, the activation of AMPK by AICAR, reduced 7beta-hydroxycholesterol level after stimulation by HDL2. Treatment with AICAR increased Abca1 (52%) and Cd36 (220%), decreased Prkaa1 (19%) e Cyp27a1 (47%), and did not change Abcg1, Nr1h3 e Nr1h2. In conclusion, in dyslipidemic mice aerobic exercise training increases the nonenzymatic-driven oxysterol, 7beta-hydroxycholesterol, which is related to the enhanced expression of Cd36. The rapid diffusion of oxysterols, as a complementary pathway for the reverse cholesterol transport, may also be favored by the increase and reduction of Cyp27a1 and Cyp7b1 expressions, respectively, which in turns favors 27-OH C desorption from cells. Together with its direct role in improving reverse cholesterol transport as previously reported, aerobic exercise training diminishes cholesterol accumulation in the arterial wall preventing atherosclerosis. Based on in vitro assays, the AMPK activation does not seem to contribute to the effect of exercise in increasing oxysterols

Os óxidos de colesterol modulam o desenvolvimento da aterosclerose por mediarem a síntese, captação e exportação de colesterol, além de inflamação e citotoxicidade na parede arterial. O exercício físico regular previne e regride a lesão aterosclerótica, por melhorar o perfil lipídico, transporte reverso de colesterol e defesas antioxidantes. A proteína cinase ativada por AMP (AMPK) é um importante mediador dos efeitos metabólicos do exercício físico. Em macrófagos, sua ativação vincula-se ao aumento no efluxo de colesterol e diminuição na captação de LDL. Entretanto, não está claro se o treinamento físico modula as concentrações de óxidos de colesterol, refletindo seu benefício sobre a prevenção da aterosclerose, e se esses efeitos podem ser mediados pela AMPK. O objetivo do presente estudo foi avaliar, em camundongos dislipidêmicos, o papel de 6 semanas de treinamento físico aeróbio sobre: o infiltrado de colesterol arterial e a distribuição de óxidos de colesterol no arco aórtico e no plasma; a expressão gênica de proteínas envolvidas na metabolização de óxidos de colesterol na parede arterial; e o efeito da ativação da AMPK em macrófagos, in vitro, sobre a concentração dos óxidos de colesterol e expressão de genes envolvidos na metabolização de óxidos de colesterol. Para tanto, camundongos machos knockout para apolipoproteína E, com 16 semanas de idade, alimentados com dieta padrão, foram incluídos no estudo. O treinamento físico foi realizado em esteira, 15 m/min, por 60 min, 5 dias/semana, durante 6 semanas. Lípides plasmáticos e glicose foram determinados por ensaio enzimático e glicosímetro, respectivamente, antes e após o treinamento físico. Colesterol arterial e óxidos de colesterol foram avaliados por cromatografia gasosa acoplada à espectrometria de massa. A expressão de genes envolvidos no metabolismo de lípides foi avaliada RT-qPCR. Os resultados foram comparados por ANOVA de um fator com pós-teste de Newman-Keuls ou teste t de Student. Peso corporal, colesterol total, TG, HDL-c, glicose e óxidos de colesterol no plasma foram semelhantes entre os grupos. O treinamento físico aumentou a concentração de 7alfa-OH C (70%) e reduziu a de colesterol (32%) na aorta. Além disso, o exercício físico aumentou a expressão gênica da Cyp27a1 (54%), Cd36 (75%), Cat (70%), Prkaa1 (AMPKalfa1) (40%) e Prkaa2 (AMPKalfa2) (51%) e reduziu Abcg1 (31%), Olr1 (LOX-1) (65%), Cyp7b1 (35%) e Ch25h (48%). Nenhuma alteração foi observada na expressão de Abca1, Nr1h3 (LXRalfa) e Nr1h2 (LXRbeta). Nos macrófagos, a ativação da AMPK por AICAR, reduziu o conteúdo de 7alfa-OH C após estimulo com HDL2. O tratamento com AICAR aumentou a expressão gênica de Abca1 (52%) e Cd36 (220%) e diminuiu Prkaa1 (19%) e Cyp27a1 (47%), e não alterou Abcg1, Nr1h3 e Nr1h2. Em conclusão, em camundongos dislipidêmicos, o treinamento físico aeróbio, por 6 semanas, aumentou a concentração de 7 beta -OH C, o que se vincula à maior expressão de Cd36 no arco aórtico. A rápida difusão de óxidos de colesterol, como via complementar ao transporte reverso de colesterol, pode também ser favorecida pelo aumento e redução, respectivamente, na expressão de Cyp27a1 e Cyp7b1, favorecendo maior liberação de 27-OH C das células. Juntamente com suas ações diretas que beneficiam o transporte reverso de colesterol, previamente descritas o treinamento físico diminui a concentração de colesterol na parede arterial, prevenindo a aterosclerose. Baseado nos ensaios in vitro a ativação da AMPK não parece contribuir para o aumento das concentrações de óxidos de colesterol após treinamento físico / Oxysterols modulate the development of atherosclerosis by mediating cholesterol synthesis, uptake and exportation as well as inflammation and cytotoxicity in the arterial wall. Regular physical exercise prevents and regresses atherosclerosis by improving lipid metabolism, reverse cholesterol transport and antioxidant defenses. AMP-activated protein kinase (AMPK) plays an important role in the beneficial metabolic adaptations of physical exercise. In macrophages, its activation is related to the enhancement in cholesterol efflux and reduction in LDL uptake. However, it is not clear whether exercise training benefits in atherosclerosis is mediated by its action in oxysterols concentrations, and whether this can be modulated by AMPK. The aim of this study was to evaluate the role of a 6-week aerobic exercise training program in dyslipidemic mice in the arterial and plasma accumulation of cholesterol and oxysterols subspecies; expression of genes related to oxysterols metabolisms in the aortic arch, and the effect of AMPK activation in macrophage on the concentration of oxysterols and expression of genes linked to oxysterols metabolism. Sixteen-week-old male apoE knockout mice fed a chow diet were included in the protocol. Animals were trained in a treadmill running, 15 m/min, 60 min, 5 days/week, during 6 weeks. Plasma lipids and glucose were determined by enzymatic techniques and glycosometer, respectively. Cholesterol in aortic arch and oxysterols were measured by gas chromatography/mass spectrometer. The expression of genes involved in lipid metabolism was determined by RT-qPCR. Results (mean ± SD) were compared by one-way ANOVA with Newman-Keuls posttest or Student\'s t-test. Body weight and plasma total cholesterol, TG, HDL-c, glucose, and oxysterols were similar among groups. The exercise training enhanced 7beta-hydroxycholesterol (70%) and reduced cholesterol (32%) in the aortic arch. In addition, exercise increased Cyp27a1 (54%), Cd36 (75%), cat (70%), Prkaa1 (AMPKalpha1) (40%) and Prkaa2 (AMPKalpha2) (51%) mRNA. No changes were observed in the expression of Abca1, Nr1h3 (LXRalpha) and Nr1h2 (LXRbeta). In macrophages, the activation of AMPK by AICAR, reduced 7beta-hydroxycholesterol level after stimulation by HDL2. Treatment with AICAR increased Abca1 (52%) and Cd36 (220%), decreased Prkaa1 (19%) e Cyp27a1 (47%), and did not change Abcg1, Nr1h3 e Nr1h2. In conclusion, in dyslipidemic mice aerobic exercise training increases the nonenzymatic-driven oxysterol, 7beta-hydroxycholesterol, which is related to the enhanced expression of Cd36. The rapid diffusion of oxysterols, as a complementary pathway for the reverse cholesterol transport, may also be favored by the increase and reduction of Cyp27a1 and Cyp7b1 expressions, respectively, which in turns favors 27-OH C desorption from cells. Together with its direct role in improving reverse cholesterol transport as previously reported, aerobic exercise training diminishes cholesterol accumulation in the arterial wall preventing atherosclerosis. Based on in vitro assays, the AMPK activation does not seem to contribute to the effect of exercise in increasing oxysterols

Les résultats des études cliniques récentes évaluant l'impact de l'augmentation du HDL-C sur la survenue des maladies cardiovasculaires n'ont pas permis de démontrer une efficacité significative de cette stratégie thérapeutique ciblée sur le HDL-C. L'évaluation de la fonctionnalité des particules HDL dans sa capacité à assurer le retour du cholestérol des tissus périphériques au foie s'avère plus importante que la simple mesure du HDL-C. L'objectif de mes travaux de recherche a été d'évaluer la fonctionnalité des particules HDL en fonction du contexte métabolique, inflammatoire et génétique de chaque individu. Mes travaux de recherche ont démontré que la niacine réduit l'athérogénicité des lipoprotéines durant la période postprandiale modulant par conséquent la fonctionnalité des particules HDL dans la voie du transport inverse de cholestérol. J'ai également montré que certaines pathologies infectieuses associées à des taux bas de HDL-C, entrainent une baisse de la capacité des particules HDL à stimuler l'efflux de cholestérol à travers le macrophage humain. En revanche, j'ai montré que des variations génétiques entrainant des taux élevés de HDL-C ne sont pas associées à une dysfonction des particules HDL dans la voie du transport inverse de cholestérol. Mes travaux soulignent l'importance de considérer que la fonctionnalité des particules HDL est modulée in vivo par des contraintes métaboliques inflammatoires et génétiques d'où il est nécessaire que les thérapies en cours de développement visant à augmenter la fonction des HDL soient résistantes aux modifications métaboliques et inflammatoires afin d'assurer une athéroprotection efficace. / HDL cholesterol as a therapeutic target has been the focus over the past 20 years mainly because its plasma concentrations are inversely correlated with the risk of coronary events. However, recent clinical trials involved the addition of niacin or CETP inhibitors to a statin in patients with CHD who had well controlled LDL-C levels have failed to show evidence of a significant reduction in cardiovascular events. Studies on the capacity of HDL to promote reverse cholesterol transport pathway have suggested that this is a better predictor of prevalent atherosclerotic disease than HDL-C itself. The main purpose of my project was to evaluate the impact of metabolic context, inflammation and genetics on modulation of HDL functionality. I have shown that extended release niacin/laropiprant treatment reduces atherogenic postprandial lipoproteins in patients with metabolic disorders stabilized by statins, having consequences on reverse cholesterol transport pathway and HDL functionality. Moreover, I have shown that infectious diseases such as HIV, induce an alteration in the capacity of HDL particles to stimulate cholesterol efflux from human macrophages. I have also shown that mutations causing high levels of HDL-C, are characterized by the presence of functional HDL in their capacity to stimulate reverse cholesterol pathway. However such patients are not systematically protected against cardiovascular disease highlighting the complex relationship between cholesterol efflux and the prediction of cardiovascular events. Those results point out the relevance of developing therapeutic approaches targeting HDL function and reverse cholesterol transport pathway.

Les maladies cardiovasculaires sont la principale cause de morbidité et de mortalité dans les pays industrialisés. Le récepteur CD36, exprimé à la surface des macrophages, joue un rôle déterminant dans l’internalisation des lipoprotéines oxydées menant à la formation des cellules spumeuses dans l’espace sous endothélial, première étape du développement des lésions athérosclérotiques. Nous avons montré précédemment que les sécrétines de l’hormone de croissance sont des ligands du récepteur CD36 qui possèdent un site de liaison qui chevauche celui des lipoprotéines oxydées. Cependant, aucune étude n’avait rapporté les effets potentiels des ligands sélectifs du CD36 sur la progression des lésions athérosclérotiques et le métabolisme lipidique au niveau des macrophages. Ainsi, ce projet de doctorat visait à évaluer le potentiel anti-athérosclérotique du EP 80317, un ligand sélectif du CD36, et élucider les mécanismes à l’origine de ses effets sur le métabolisme et le transport des lipides au niveau des macrophages. À cette fin, des souris déficientes en apolipoprotéine E (apoE-/-), nourries avec une diète riche en lipides et en cholestérol, ont été traitées quotidiennement pendant 12 semaines avec le EP 80317, montrant un puissant effet anti-athérosclérotique associé à une réduction de 51% des lésions aortiques et de 30% du taux plasmatique de cholestérol total. Cette même étude a permis de montrer une réduction de l’internalisation des lipoprotéines oxydées ainsi qu’une augmentation de l’expression des gènes/protéines impliqués dans l’efflux du cholestérol au niveau des macrophages, comme le peroxisome proliferator-activated receptor γ (PPARγ), liver x receptor α (LXRα) et les transporteurs ABCA1 et ABCG1, entraînant une réduction de la formation des cellules spumeuses. Ces observations nous ont conduits à élucider les mécanismes moléculaires engendrés par la liaison d’un ligand sélectif au récepteur CD36 dans les macrophages. Les études ont permis de montrer que les ligands du CD36 entraînent une augmentation de l’efflux du cholestérol vers les transporteurs ABCA1 et ABCG1 en augmentant l’expression protéique de la cyclooxygénase 2 (COX-2) consécutive à la phosphorylation de la MAP kinase ERK1/2. L’activation de COX-2 stimule la production intracellulaire de la prostaglandine 15d-PGJ2, cette dernière conduisant à l’activation du PPARγ. Finalement, une troisième étude nous a permis de mettre en évidence les effets du EP 80317 sur le transport inverse du cholestérol in vivo. L’injection de macrophages J774 radiomarqués avec du cholestérol tritié dans la cavité péritonéale de souris avec le EP 80317 nous a permis de montrer que le EP 80317 entraîne une réduction de la radioactivité retrouvée dans le foie tandis qu’il augmente celle retrouvée dans les fèces par comparaison aux souris contrôles, sans néanmoins modifier le profil plasmatique du radiotraceur entre les deux groupes. De plus, l’expression des gènes impliqués dans le transport du cholestérol au niveau intestinal comme le LXRα, ABCA1, ABCG5 ainsi que ABCG8 ont été régulés à la hausse par le EP 80317 tandis que l’expression de NPC1L1, un transporteur impliqué dans l’absorption du cholestérol, a été régulé à la baisse. Toutefois, les gènes impliqués dans le métabolisme du cholestérol au niveau du foie ne sont pas modulés par le EP 80317. En conclusion, les travaux effectués dans le cadre de cette thèse nous ont permis de montrer que l’activation du récepteur CD36 par le EP 80317 pourrait s’avérer être une nouvelle approche thérapeutique pour le traitement de l’athérosclérose. Les effets anti-athérosclérotiques et hypocholestérolémiants des ligands synthétiques du récepteur CD36 sont en partie engendrés par 1) la régulation du métabolisme des lipides au niveau des macrophages en réponse à l’activation du PPARγ par son ligand endogène, le 15d-PGJ2 et 2) par une augmentation du transport inverse du cholestérol, particulièrement par une augmentation de l’efflux transintestinal. / Cardiovascular diseases are the major cause of mortality and morbidity in industrialized countries. CD36, a type B scavenger receptor expressed on macrophages, appears to play a major role in foam cell formation through scavenging oxidatively modified lipoproteins, thus leading to fatty streak lesion formation in the arterial wall. We have previously reported that growth hormone-releasing peptides (GHRP) are synthetic ligands that share the same binding site as oxidized low density lipoprotein (oxLDL) on the CD36 receptor. However, no study has reported the anti-atherosclerotic effects of CD36 ligands and their role in macrophage lipid metabolism. Thus, this project aimed to evaluate the anti-atherosclerotic effects of EP 80317, a CD36 selective ligand, and to elucidate the role of GHRP on macrophage lipid metabolism and transport. Apolipoprotein E deficient mice (apoE-/-) fed a high fat high cholesterol diet were treated for 12 weeks with EP 80317. Our study showed that EP 80317 exerted potent anti-atherosclerotic effects as shown by reduced lesion areas (up to 51%) and hypocholesterolemia. We further showed that a chronic treatment with EP 80317 reduced oxLDL uptake and increased the expression of genes/proteins involved in macrophage cholesterol efflux, such as peroxisome proliferator-activated receptor γ (PPARγ), liver x receptor α (LXRα) and ATP-binding cassette A1 (ABCA1) and ABCG1, thus reducing foam cell formation. Our second study aimed to elucidate the molecular mechanisms by which CD36 ligands lead to an increase in macrophage cholesterol efflux following PPARγ activation. [3H]-cholesterol-labeled murine macrophages incubated in the presence of EP 80317 showed a significant increase in cholesterol efflux to both ABCA1 and ABCG1 transporters of cholesterol. EP 80317-mediated macrophage cholesterol efflux through PPARγ involved an increase in intracellular 15d-PGJ2 levels that were elicited by extracellular signal-regulated kinase 1/2 (ERK1/2) stimulation, itself dependent on COX-2 activation. The third and last study of this thesis aimed to investigate the effect of CD36 selective ligand on reverse cholesterol transport in vivo. ApoE-/- mice treated or not with EP 80317 were injected intraperitoneally with [3H]-cholesterol-labeled murine J774 macrophage-like cells. The radioactivity recovered in the livers of EP 80317-treated mice was significantly lower than that found in vehicle-treated mice whereas feces radioactivity was higher. Yet, the radioactivity in plasma did not achieve statistical differences between the two groups. Furthermore, the expression of genes involved in intestinal cholesterol transport such as LXRα, ABCA1, ABCG5 and ABCG8 was upregulated in EP 80317-treated mice while the expression of NPC1L1, a transporter involved in cholesterol absorption, was downregulated compared to vehicle-treated mice. In contrast, genes involved in hepatic cholesterol metabolism were not modulated by EP 80317. In conclusion, the work conducted in this thesis supported that activation of CD36 signaling pathways by EP 80317 may constitute a novel therapeutic approach for the treatment of atherosclerosis. The anti-atherosclerotic and hypocholesterolemic effects of synthetic CD36 selective ligands might be explained, at least in part, by 1) the regulation of macrophage cholesterol metabolism as a result of an increase in PPARγ activation by its endogenous ligand, 15d-PGJ2 and 2) the stimulation of reverse cholesterol transport, in particular that of transintestinal cholesterol efflux.

Les maladies cardiovasculaires sont la principale cause de morbidité et de mortalité dans les pays industrialisés. Le récepteur CD36, exprimé à la surface des macrophages, joue un rôle déterminant dans l’internalisation des lipoprotéines oxydées menant à la formation des cellules spumeuses dans l’espace sous endothélial, première étape du développement des lésions athérosclérotiques. Nous avons montré précédemment que les sécrétines de l’hormone de croissance sont des ligands du récepteur CD36 qui possèdent un site de liaison qui chevauche celui des lipoprotéines oxydées. Cependant, aucune étude n’avait rapporté les effets potentiels des ligands sélectifs du CD36 sur la progression des lésions athérosclérotiques et le métabolisme lipidique au niveau des macrophages. Ainsi, ce projet de doctorat visait à évaluer le potentiel anti-athérosclérotique du EP 80317, un ligand sélectif du CD36, et élucider les mécanismes à l’origine de ses effets sur le métabolisme et le transport des lipides au niveau des macrophages. À cette fin, des souris déficientes en apolipoprotéine E (apoE-/-), nourries avec une diète riche en lipides et en cholestérol, ont été traitées quotidiennement pendant 12 semaines avec le EP 80317, montrant un puissant effet anti-athérosclérotique associé à une réduction de 51% des lésions aortiques et de 30% du taux plasmatique de cholestérol total. Cette même étude a permis de montrer une réduction de l’internalisation des lipoprotéines oxydées ainsi qu’une augmentation de l’expression des gènes/protéines impliqués dans l’efflux du cholestérol au niveau des macrophages, comme le peroxisome proliferator-activated receptor γ (PPARγ), liver x receptor α (LXRα) et les transporteurs ABCA1 et ABCG1, entraînant une réduction de la formation des cellules spumeuses. Ces observations nous ont conduits à élucider les mécanismes moléculaires engendrés par la liaison d’un ligand sélectif au récepteur CD36 dans les macrophages. Les études ont permis de montrer que les ligands du CD36 entraînent une augmentation de l’efflux du cholestérol vers les transporteurs ABCA1 et ABCG1 en augmentant l’expression protéique de la cyclooxygénase 2 (COX-2) consécutive à la phosphorylation de la MAP kinase ERK1/2. L’activation de COX-2 stimule la production intracellulaire de la prostaglandine 15d-PGJ2, cette dernière conduisant à l’activation du PPARγ. Finalement, une troisième étude nous a permis de mettre en évidence les effets du EP 80317 sur le transport inverse du cholestérol in vivo. L’injection de macrophages J774 radiomarqués avec du cholestérol tritié dans la cavité péritonéale de souris avec le EP 80317 nous a permis de montrer que le EP 80317 entraîne une réduction de la radioactivité retrouvée dans le foie tandis qu’il augmente celle retrouvée dans les fèces par comparaison aux souris contrôles, sans néanmoins modifier le profil plasmatique du radiotraceur entre les deux groupes. De plus, l’expression des gènes impliqués dans le transport du cholestérol au niveau intestinal comme le LXRα, ABCA1, ABCG5 ainsi que ABCG8 ont été régulés à la hausse par le EP 80317 tandis que l’expression de NPC1L1, un transporteur impliqué dans l’absorption du cholestérol, a été régulé à la baisse. Toutefois, les gènes impliqués dans le métabolisme du cholestérol au niveau du foie ne sont pas modulés par le EP 80317. En conclusion, les travaux effectués dans le cadre de cette thèse nous ont permis de montrer que l’activation du récepteur CD36 par le EP 80317 pourrait s’avérer être une nouvelle approche thérapeutique pour le traitement de l’athérosclérose. Les effets anti-athérosclérotiques et hypocholestérolémiants des ligands synthétiques du récepteur CD36 sont en partie engendrés par 1) la régulation du métabolisme des lipides au niveau des macrophages en réponse à l’activation du PPARγ par son ligand endogène, le 15d-PGJ2 et 2) par une augmentation du transport inverse du cholestérol, particulièrement par une augmentation de l’efflux transintestinal. / Cardiovascular diseases are the major cause of mortality and morbidity in industrialized countries. CD36, a type B scavenger receptor expressed on macrophages, appears to play a major role in foam cell formation through scavenging oxidatively modified lipoproteins, thus leading to fatty streak lesion formation in the arterial wall. We have previously reported that growth hormone-releasing peptides (GHRP) are synthetic ligands that share the same binding site as oxidized low density lipoprotein (oxLDL) on the CD36 receptor. However, no study has reported the anti-atherosclerotic effects of CD36 ligands and their role in macrophage lipid metabolism. Thus, this project aimed to evaluate the anti-atherosclerotic effects of EP 80317, a CD36 selective ligand, and to elucidate the role of GHRP on macrophage lipid metabolism and transport. Apolipoprotein E deficient mice (apoE-/-) fed a high fat high cholesterol diet were treated for 12 weeks with EP 80317. Our study showed that EP 80317 exerted potent anti-atherosclerotic effects as shown by reduced lesion areas (up to 51%) and hypocholesterolemia. We further showed that a chronic treatment with EP 80317 reduced oxLDL uptake and increased the expression of genes/proteins involved in macrophage cholesterol efflux, such as peroxisome proliferator-activated receptor γ (PPARγ), liver x receptor α (LXRα) and ATP-binding cassette A1 (ABCA1) and ABCG1, thus reducing foam cell formation. Our second study aimed to elucidate the molecular mechanisms by which CD36 ligands lead to an increase in macrophage cholesterol efflux following PPARγ activation. [3H]-cholesterol-labeled murine macrophages incubated in the presence of EP 80317 showed a significant increase in cholesterol efflux to both ABCA1 and ABCG1 transporters of cholesterol. EP 80317-mediated macrophage cholesterol efflux through PPARγ involved an increase in intracellular 15d-PGJ2 levels that were elicited by extracellular signal-regulated kinase 1/2 (ERK1/2) stimulation, itself dependent on COX-2 activation. The third and last study of this thesis aimed to investigate the effect of CD36 selective ligand on reverse cholesterol transport in vivo. ApoE-/- mice treated or not with EP 80317 were injected intraperitoneally with [3H]-cholesterol-labeled murine J774 macrophage-like cells. The radioactivity recovered in the livers of EP 80317-treated mice was significantly lower than that found in vehicle-treated mice whereas feces radioactivity was higher. Yet, the radioactivity in plasma did not achieve statistical differences between the two groups. Furthermore, the expression of genes involved in intestinal cholesterol transport such as LXRα, ABCA1, ABCG5 and ABCG8 was upregulated in EP 80317-treated mice while the expression of NPC1L1, a transporter involved in cholesterol absorption, was downregulated compared to vehicle-treated mice. In contrast, genes involved in hepatic cholesterol metabolism were not modulated by EP 80317. In conclusion, the work conducted in this thesis supported that activation of CD36 signaling pathways by EP 80317 may constitute a novel therapeutic approach for the treatment of atherosclerosis. The anti-atherosclerotic and hypocholesterolemic effects of synthetic CD36 selective ligands might be explained, at least in part, by 1) the regulation of macrophage cholesterol metabolism as a result of an increase in PPARγ activation by its endogenous ligand, 15d-PGJ2 and 2) the stimulation of reverse cholesterol transport, in particular that of transintestinal cholesterol efflux.